Cost-effectiveness analysis of rifaximin-{alpha} administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France

Conclusion: For the societal willingness to pay threshold of 27,000 per QALY gained, rifaximin-α in combination with lactulose is a cost-effective and affordable treatment for patients who have experienced at least two prior overt HE episodes.
Source: Therapeutic Advances in Gastroenterology - Category: Gastroenterology Authors: Tags: Original Research Source Type: research